The “Pace Me” platform ingeniously integrates a wearable activity tracker, specifically a Fitbit watch, with an intelligent mobile application that delivers timely, context-aware notifications throughout the day. These alerts serve as behavioral nudges, cautioning users before they potentially exceed their energy limits—a condition often exacerbating symptoms for those with Long COVID. This symbiotic wearable-app duo represents a novel approach by providing real-time feedback that empowers users to carefully balance activity and rest, mitigating episodes of symptom flare-ups.

Conceptualized and led by Dr. Lawrence Hayes from Lancaster University, along with Dr. Nilihan Sanal-Hayes and Professor Nicholas Sculthorpe, the trial stands as a beacon of multidisciplinary collaboration aimed at addressing the complex clinical challenge posed by Long COVID. The trial was meticulously designed, recruiting 250 participants who were randomized into two cohorts. The intervention group was equipped with the complete “Pace Me” system featuring active tracking and alert functionalities. In contrast, the control group used a version of the app restricted to data input screens, devoid of any tracking or proactive alerts, effectively serving as a placebo comparator.

What distinguishes this trial is its focus on PEM as a primary outcome measure—an intense exacerbation of symptoms following exertion, which notoriously hampers recovery in Long COVID sufferers. Over a span of six months, the study rigorously quantified both subjective symptom reports and objective wearable data. Although both cohorts exhibited symptomatic improvements, the digitally assisted intervention did not significantly outperform the control group in reducing PEM incidence overall. Remarkably, however, about 13 participants in the intervention arm transitioned from PEM-positive to PEM-negative status, with a notable 10% reduction in participants reporting PEM compared to baseline.

While the overall efficacy signal was modest, Dr. Hayes emphasizes that the safety profile and acceptability of the digital platform mark a vital milestone. The study validates the feasibility of deploying adaptive digital health tools for energy management in post-viral syndromes, an area historically underserved by conventional therapeutic strategies. This innovation opens the door for iterative refinement and targeted development that could cater to chronic conditions where symptom persistence and flare-ups predominate, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), multiple sclerosis, and autoimmune diseases like lupus.

The trial’s methodological rigor lies in leveraging real-time physiological data to create personalized intervention thresholds, dynamically adjusting behavioral prompts in accordance with each user’s fluctuating capacity. This approach embodies a paradigm shift from static rehabilitation protocols to precision digital therapeutics, capable of delivering scalable and remotely accessible care solutions aligned with contemporary health system priorities. The design also highlights the importance of integrating user feedback loops within digital health ecosystems to optimize engagement and therapeutic adherence.

Importantly, the researchers contextualize their findings within broader health policy frameworks, referencing the NHS Long Term Plan and the Darzi report, both of which champion the digital transformation of healthcare delivery to improve chronic illness management. The platform’s adaptability signifies its potential for expansion beyond Long COVID to encompass diverse pathologies characterized by energy dysregulation and symptom exacerbation post-activity, thus presenting a versatile tool in the digital health arsenal.

Despite the lack of a statistically superior outcome relative to usual care, the learnings from this trial underscore critical considerations for future research. These include the need for refined algorithms that can better discriminate between safe and excessive activity levels, enhanced user interface designs to facilitate intuitive interaction, and integration with multidisciplinary care teams to provide holistic disease management. Emerging evidence from this study lays a vital foundation for subsequent trials exploring digital therapeutics in syndromes with overlapping pathophysiological and symptom profiles.

This investigation also calls attention to the nuanced trajectory of recovery in Long COVID compared to other chronic illnesses, advocating for digital tools that are tailored not only to individual patients but also to disease-specific progression patterns. Such precision aligns with the evolving paradigm of personalized medicine and underscores the necessity for multi-modal intervention strategies that incorporate physiological monitoring, symptom reporting, and psychosocial support within a unified platform.

In closing, the “Pace Me” digital tool heralds a promising frontier in the chronic disease management domain by harnessing wearable technology and real-time analytics to empower patients in self-regulating their activity. While further technological enhancement and clinical validation are warranted, this pioneering study delineates a compelling framework for leveraging digital platforms to ameliorate the burdens of Long COVID and potentially other fatiguing conditions that challenge conventional treatment paradigms.

Subject of Research: People

Article Title: A Digital Platform with Activity Tracking for Energy Management Support in Long COVID: A Randomised Controlled Trial

News Publication Date: 2-Feb-2026

Web References: http://dx.doi.org/10.1038/s41467-025-64831-y

Image Credits: Lancaster University

Keywords: Long COVID, Human health, Chronic fatigue syndrome, Information technology, Smartphones, Health care, Health care delivery

The core technological platform employed was BrainHQ, a commercially available brain exercise app developed by Posit Science, renowned for its evidence-based, neuroscience-driven cognitive training programs. These programs utilize adaptive algorithms that continuously calibrate task difficulty, stimulating targeted neural circuits to promote synaptic strengthening and cortical reorganization. By pushing cognitive boundaries through progressively challenging exercises, the intervention intensifies neuroplastic mechanisms that undergird recovery processes. Notably, this approach contrasts with traditional passive or pharmacologic treatments by actively engaging patients in tailored mental workouts that translate into meaningful real-world functional gains.

Long COVID’s burden in the United States alone is staggering, with estimates suggesting approximately 20 million individuals have been diagnosed and 9 to 10 million still experiencing lingering symptoms. A significant subset, roughly 14%, remain unable to resume their occupational roles even three months following initial infection, underscoring the urgent need for evidence-based rehabilitative strategies. The UAB study enrolled 16 community-dwelling adults, all more than three months post-COVID infection and exhibiting mild cognitive impairment alongside difficulties in managing instrumental activities of daily living. Participants were randomized into either the intervention group receiving BrainHQ exercises coupled with coaching or a wait-list control group, ensuring rigorous scientific evaluation.

Results from this early-phase trial were striking, with the intervention cohort demonstrating statistically significant and notably large improvements in key outcome measures related to cognitive performance and daily activity satisfaction. Secondary measures bore equally encouraging findings, highlighting substantial reductions in depression, fatigue, and the hallmark “brain fog” associated with Long COVID. Moreover, participants exhibited enhanced brain processing speeds, an objective neurocognitive marker often diminished in post-viral syndromes. While global cognition metrics did not shift significantly, the targeted effects on specific cognitive domains and symptom clusters represent a meaningful therapeutic advance.

Perhaps most remarkable was the functional impact observed: 80% of the active working-age participants in the intervention arm successfully returned to their jobs, a stark contrast to the control group where no such return was reported. This real-world outcome solidifies the potential of neuroplasticity-centered interventions to restore not only cognitive faculties but also vocational capacity, a critical determinant of quality of life and socioeconomic wellbeing. The robust coaching component, inspired by constraint-induced movement therapy principles, provided motivational scaffolding and fostered sustained engagement with the challenging training regimen, possibly amplifying the neuroplastic effects.

The scientific underpinnings of this intervention are deeply rooted in decades of neuroplasticity research, with foundational contributions from Dr. Michael Merzenich, whose seminal work demonstrated that adult brains retain the capacity for profound chemical, structural, and functional remodeling throughout life. Dr. Merzenich’s pioneering insights, which catalyzed the development of cochlear implants, have since evolved toward designing computerized exercises that simulate the brain’s natural learning processes. His role as co-founder and chief scientific officer of Posit Science ensures that cutting-edge neuroscience informs BrainHQ’s evolving exercise protocols.

At UAB, further refinement of neuroplasticity-based rehabilitation has been driven by the work of Dr. Karlene Ball and Dr. Edward Taub. Dr. Ball’s efforts elucidated the potential of plasticity-oriented exercises to mitigate age-related cognitive decline, while Dr. Taub’s development of constraint-induced movement therapy revolutionized rehabilitation approaches to movement disorders by compelling use-dependent cortical reorganization. Their expertise informed the coaching methodology integrated into this study, which supported progressive challenge and incremental mastery—key elements known to potentiate durable neural adaptation.

Prior applications of BrainHQ exercises in populations including older adults and patients with various chronic illness states—such as cancer, heart failure, multiple sclerosis, schizophrenia, and mild cognitive impairment—have documented cognitive and functional gains, including improvements in depressive symptoms, fatigue, and employment status. However, the magnitude of improvements realized in this Long COVID cohort surpasses many earlier findings, potentially attributable to the greater baseline impairment and the synergistic effect of combining brain exercise with targeted coaching. This combination may represent a critical innovation in neurorehabilitation strategies.

From a mechanistic perspective, intensive, repetitive, and progressively challenging cognitive tasks are postulated to drive synaptic strengthening via long-term potentiation, augment myelination, and promote neurogenesis in hippocampal and prefrontal circuits. Such neurophysiological adaptations could counteract the neuroinflammatory and microvascular insults hypothesized to underlie Long COVID cognitive dysfunction. Enhancing processing speed likely reflects improvements in white matter integrity and neural network efficiency, foundational to higher-order executive function and daily task performance.

Dr. Henry Mahncke, CEO of Posit Science, underscored the promise of brain training as a non-pharmacologic intervention, stating that the observed benefits may herald a turning point in Long COVID management. Given the substantial unmet clinical need, scalable digital therapeutics like BrainHQ offer an accessible, cost-effective, and patient-empowering avenue for rehabilitation, suitable for deployment across diverse healthcare settings.

The study’s modest sample size and primary focus on feasibility highlight the necessity for expanded trials to confirm efficacy and explore long-term outcomes. Nonetheless, these initial findings inject critical optimism into a field marked by diagnostic ambiguity and therapeutic inertia. Future research directions include elucidating neurobiological correlates of response via neuroimaging, optimizing cognitive exercise protocols for personalized intervention, and investigating combinatorial approaches integrating cognitive training with pharmacotherapies or physical rehabilitation.

BrainHQ’s extensive validation across over 300 peer-reviewed studies substantiates its broad applicability and underscores its potential as a foundational tool in cognitive health. The platform’s adoption by Medicare Advantage plans, academic medical centers, and peak performance organizations attests to its versatility and clinical relevance. Individuals can access a free daily exercise via the platform’s website, democratizing cognitive health resources.

In summary, this pioneering controlled trial signifies a major step forward in Long COVID treatment, illustrating that harnessing neuroplasticity through structured brain exercises and coaching not only ameliorates debilitating cognitive symptoms but also restores individuals’ ability to engage meaningfully in daily life and work. As Long COVID continues to impose a heavy societal toll, tech-enabled neurorehabilitation may emerge as a pivotal element in comprehensive recovery paradigms.

—

Subject of Research: People
Article Title: Long COVID brain fog treatment: An early-phase randomized controlled trial of constraint-induced cognitive therapy signals go.
News Publication Date: May 5, 2025
Web References:
– https://psycnet.apa.org/doiLanding?doi=10.1037%2Frep0000626
– https://www.brainhq.com/
– https://www.cidrap.umn.edu/covid-19/about-8-us-adults-have-ever-had-long-covid-survey-finds
– https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300947
– http://dx.doi.org/10.1037/rep0000626
– https://www.brainhq.com/world-class-science/science-team-research-partners/dr-michael-merzenich-phd/
– https://www.uab.edu/cas/psychology/people/faculty/karlene-k-ball
– https://www.uab.edu/cas/psychology/people/emeritus-faculty/edward-taub
– https://www.brainhq.com/world-class-science/information-researchers/
– https://www.brainhq.com/world-class-science/the-proven-benefits-of-brainhq

References: 10.1037/rep0000626 (Rehabilitation Psychology Journal Article)

Keywords: Health and medicine, Diseases and disorders, Health care, Human health, Medical cybernetics